Published in Medical Imaging Law Weekly, August 2nd, 2005
Results highlighted sustained beneficial effects on cerebral axonal injury and the value of starting Copaxone treatment early to slow the accumulation of long-term disability as measured by the Expanded Disability Status Scale (EDSS).
Brain n-acetyl aspartate (NAA) levels, a marker of neuronal integrity and function, are measured by magnetic resonance spectroscopy (MRS). An increase in brain NAA levels...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Imaging Law Weekly